Bisphosphonates in the treatment of metabolic bone diseases

被引：13
|
作者：
Arantes, Henrique Pierotti [1 ]
da Silva, Andre Goncalves [1 ]
Lazaretti-Castro, Marise [1 ]
机构：
[1] Univ Fed Sao Paulo Unifesp, Unidade Metab Osseo & Mineral, Dept Endocrinol, Sao Paulo, Brazil
来源：
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA | 2010年 / 54卷 / 02期
关键词：
Bisphosphonates; mechanism of action; osteoporosis treatment; side effects; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL OSTEOPOROSIS; ZOLEDRONIC ACID; ORAL IBANDRONATE; MINERAL DENSITY; HIP FRACTURE; WOMEN; ALENDRONATE; RISEDRONATE;
D O I：
10.1590/S0004-27302010000200017
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Osteoporosis is a disease characterized by low bone mass associated with the deterioration of microarchitecture, due to an imbalance either in high bone resorption or low bone formation or in both, leading to a high risk of fractures. Bisphosphonates are medications which reduce the ability of osteoclasts to induce bone resorption and consequently improve the balance between resorption and formation. There are bisphosphonates approved for the prevention and treatment of osteoporosis. Administration can be oral (daily, weekly or monthly) or intravenous (quarterly or yearly). These medications are well tolerated and with the correct instructions of administration have a good safety profile. Serious side effects, such as, osteonecrosis of jaw is very rare. Bisphosphonates are the most prescribed medication for the treatment of osteoporosis. Arq Bras Endocrinol Metab. 2010;54(2):206-12
引用
收藏
页码：206 / 212
页数：7
相关论文
共 50 条
12345